Mike Driver
One Nice Bug Per Day
No title available
Love Begins
hello vonnie
Show & Tell
h
Today's Document
if i look back, i am lost
The Bowery Presents
official daine visual archive
cherry valley forever
pixel skylines
titsay
tannertan36
occasionally subtle
ellievsbear
🪼
Fieri Frames
Color Me Curious
seen from United Kingdom
seen from United States
seen from United Kingdom
seen from United States
seen from United States
seen from Colombia
seen from United States
seen from United States
seen from United States
seen from United States
seen from Ukraine
seen from United Kingdom
seen from T1
seen from United States
seen from Bangladesh
seen from United States
seen from United States
seen from United States
seen from Argentina
seen from United States
@i-jacoblogan-blog
US technology company Microsoft has launched its new retail solution to enhance online and offline shopping experience for consumers.
US technology company Microsoft has launched its new retail solution to enhance the online and offline shopping experience for consumers. The Microsoft Synchronized Shopping solution makes use of ‘intelligent Cloud technology’ and has been developed in partnership with its Gold partner Popcornapps.
Cancer Research UK has announced a new £56m research network to transform the UK into a global hub for radiotherapy research.
Cancer Research UK has announced a £56m research network to transform the UK into a global hub for radiotherapy study. By leveraging the use of the latest techniques, such as FLASH radiotherapy and artificial intelligence (AI), the network aims to accelerate the development of advanced radiotherapy.
Oil prices have slightly edged higher on China’s factory data but are on track for a weekly loss.
Oil prices have slightly edged higher on China’s factory data but are on track for a weekly loss.Brent crude futures were down $0.27 at $59.89 a barrel, while US West Texas Intermediate (WTI) crude futures were down $0.32 at $54.50 per barrel, reported Reuters.
North American travel retailer Hudson Group has agreed to purchase a controlling stake in beverage concessions operator OHM Concession Group’s (OHM) assets.
North American travel retailer Hudson Group has agreed to purchase a controlling stake in beverage concessions operator OHM Concession Group’s (OHM) assets.
It is estimated that 11,000 new cases of GBM are diagnosed every year and the five-year survival rate is between 5 and 10%.
Researchers from the Abramson Cancer Center of the University of Pennsylvania have found that liquid biopsy can help to predict the prognosis of glioblastoma(GBM), the most aggressive and common brain cancer in adults.
British multinational retailer Marks & Spencer (M&S) has unveiled plans to launch instalment payments facility online for its UK customers.
British retailer Marks & Spencer (M&S) has unveiled plans to launch an instalment payments facility online for its UK customers. On M&S.com, customers will now be able to pay interest-free within six weeks of purchasing M&S clothing and home products.
MedRhythms has launched its five-site randomised controlled trial (RCT) at rehabilitation hospitals to examine a post-stroke walking rehabilitation device.
MedRhythms, a US-based digital therapeutics company, has launched its five-site randomised controlled trial (RCT) at rehabilitation hospitals and research centres to examine a post-stroke walking rehabilitation device.
Novigenix has presented positive results from its new early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.
Immuno-Transcriptomics firm Novigenix has received positive results from its early colon cancer detection blood test at the European Society for Medical Oncology (ESMO) 2019.
Patients with advanced non-small cell lung cancer may have tumour biopsy replaced with a simple blood test to assess their treatment options
Patients with advanced non-small cell lung cancer (NSCLC) may soon be offered a blood test to assess their treatment options, instead of having to provide a tumour sample for analysis.
Cancer treatment: Two studies presented at the ESMO 2019 indicated that many new anti-cancer medicines added little clinical benefit for patients.
Advances in cancer treatments, such as immunotherapies and precision medicines, have been associated with a corresponding rise in the cost of new and innovative medicines.
Pharmaceutical companies are focusing on the development of combination treatments for heavily pre-treated and refractory patient populations.
Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.
ESMO 2019 conference on medical oncology has these seven promising digital health intervention companies participating in the conference held in Barcelona, Spain from 27 September-1 October 2019.
Digital health interventions (DHIs) are fast emerging as vital tools to promote personal health and provide essential services. DHIs can be accessed through mobile phones, tablets and computers, as well as serve as effective support systems to improve personal health.
A research team led by the University of Strathclyde has developed a new AI-based blood test for the diagnosis of brain cancer.
A research team led by the University of Strathclyde in the UK has developed an artificial intelligence (AI)-based blood test for the diagnosis of brain cancer.
ImmunoGen has presented full data from Phase 3 Forward I study of Mirvetuximab Soravtansine in ovarian cancer at the ESMO 2019 Congress
ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).
Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.
Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.
At ESMO 2019 Congress, Merck unveiled interim results from pivotal neoadjuvant/adjuvant phase 3 Keynote-522 trial during Presidential Symposium.
A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.
At ESMO 2019, Samsung Bioepis reveals positive results from Phase 3 study comparing its SB8 with Avastin in patients with metastatic or recurrent NSCLC.
A Phase 3 study comparing Samsung Bioepis’ SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).